[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Basel, 21 July 2022Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follic...
Source: Roche Media News - July 21, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche achieves good results in the first six months of 2022
Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down furtherDiagnostics Divisionsales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the yearIFRSnet income increases by 12% (12% in Swiss francs), whilecore earnings per share are up 11%Highlights in the second quarter:EU approvals ofPolivy (first-line treatment for aggressive form of blood cancer),Lunsumio (follicular lymphoma) andT...
Source: Roche Investor Update - July 21, 2022 Category: Pharmaceuticals Source Type: news

Reducing sexually transmitted infections [NG221], NICE (published 15th June 2022)
Guideline covers interventions to prevent sexually transmitted infections (STIs) in people from 16yrs age. It aims to reduce the transmission of all STIs, including HIV,& includes ways to help increase uptake of STI testing& vaccines for human papillomavirus& hepatitis A&B. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 16, 2022 Category: Consumer Health News Source Type: news

Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV).1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche ’s HPV self sampling solution expands access to HPV screening options by enabling patients to privately collect their sample while at a healthcare...
Source: Roche Investor Update - June 16, 2022 Category: Pharmaceuticals Source Type: news

Roche launches human papillomavirus (HPV) self-sampling solution, expanding cervical cancer screening options
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by infection with Human Papillomavirus (HPV).1Nearly nine out of 10 women who die from cervical cancer live in low- and middle-income countries.2For patients living in areas with limited healthcare resources, increasing access to screening and decreasing barriers to sample collection are keys to ultimately preventing this disease.Roche ’s HPV self sampling solution expands access to HPV screening options by enabling patients to privately collect their sample while at a healthcare...
Source: Roche Media News - June 16, 2022 Category: Pharmaceuticals Source Type: news

5-Year Interval for Cervical Cancer Screening Safe in HPV-Negative Women
(MedPage Today) -- Women ages 24 to 49 who initially test negative for the human papillomavirus (HPV) can be safely screened for cervical cancer at 5-year intervals, according to results from a U.K. study. Using data from the first and second... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 3, 2022 Category: Hematology Source Type: news

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Media News - May 12, 2022 Category: Pharmaceuticals Source Type: news

Roche enters partnership with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure
Almost half of the world ’s population has no or limited access to diagnosticsThis situation is especially acute in low- and middle-income countries (LMICs) where diagnostics plays a critical role for treating and containing the spread of infectious diseases such as Tuberculosis (TB) and HIVNew partnership between Roche and the Global Fund supports low- and middle-income countries in broadening access to diagnostics, helping millions of previously undiagnosed people with TB and HIV get diagnosed and eventually treatedBasel, 12 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY), through its Global Access Program, and The Globa...
Source: Roche Investor Update - May 12, 2022 Category: Pharmaceuticals Source Type: news

Hope for cancer patients
University of Edinburgh researchers discovered the test, known as a liquid biopsy, can accurately predict if cancer caused by human papillomavirus (HPV) is going to come back. (Source: the Mail online | Health)
Source: the Mail online | Health - May 1, 2022 Category: Consumer Health News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news

Menstrual Blood Sequencing Effective for HPV Screening Menstrual Blood Sequencing Effective for HPV Screening
Screening for human papillomavirus in high-risk individuals may be done effectively and noninvasively using menstrual blood testing with target-capture sequencing, a clinical study suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 26, 2022 Category: Pathology Tags: Infectious Diseases News Source Type: news

Cancer breakthrough: New blood test may detect cancer earlier and more accurately
THE HUMAN papillomavirus is a group of STDs that can produce cancer in several areas of the body. The most common type of cancer is in the head and neck, and a new blood test may make catching it easier. Symptoms of head and neck cancer can include a sore threat, change in voice and pain in the ears. (Source: Daily Express - Health)
Source: Daily Express - Health - December 8, 2021 Category: Consumer Health News Source Type: news

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over the past two decad...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

American Society for Colposcopy and Cervical Pathology discusses updated American Cancer Society guidelines on cervical cancer screening
(Wolters Kluwer Health) Last year, the American Cancer Society (ACS) issued an updated set of guidelines for cervical cancer screening - emphasizing the shift toward screening with primary human papillomavirus (HPV) testing. While the ACS recommendation accounts for a transition period to implement primary HPV screening, additional factors should be considered to operationalize these guidelines, according to a special white paper in the July issue of the Journal of Lower Genital Tract Disease (JLGTD), official journal of ASCCP. The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news